Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- CDFS Subcommittee to Discuss Safety Measures for Mylotarg
November 1, 2010
- Precaution Statements to Be Revised for Ketoprofen-Based OTC Drugs
November 1, 2010
- Takeda Sets Up Global Business Development Organization
November 1, 2010
- PMDA to Have Fewer Active Officials Dispatched from Korosho
November 1, 2010
- Daiichi Sankyo Healthcare Voluntarily Recalls Skin Cream
November 1, 2010
- Takara Bio Acquires Oncology Business from M's Science
November 1, 2010
- Daiichi Sankyo: Anti-Flu Drug Inavir
November 1, 2010
- The Pharma Gospel of Praise
November 1, 2010
- Nobelpharma Considers Independent Marketing of New Products
November 1, 2010
- Nichi-Iko Ties Up with Aprogen of South Korea for Biosimilars
November 1, 2010
- Fixed-Dose ARB/CCB Combinations Reduce ADRs: Prof. Hasebe
November 1, 2010
- Pfizer Acquires 40% Stake in Brazilian Generic Company
November 1, 2010
- Generics' Share in Japan Will Not Become as Large as in the West: Prof. Nakamura
November 1, 2010
- COPD Treatments, Smoking Cessation Aids to Show Double-Digit Growth: Fuji-Keizai
November 1, 2010
- Mediscience: FY2010 Business Results Fall Short of Forecasts
November 1, 2010
- IMSUT Objects to Asahi Shimbun News
November 1, 2010
- JMA, JAMS Oppose JSLN's Cholesterol GL for Longevity
November 1, 2010
- BI Inaugurates New Inhaler Factory
November 1, 2010
- Japan Can Contribute to Global Development by Earlier Participation: Dr Yoshikawa of Eli Lilly Japan
November 1, 2010
- 5-Fold Increase in Pollen Counts Expected in Spring 2011
November 1, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…